# S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

Source: https://onco.cc/trials/nct06188702/  
OnCo record `nct06188702` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TNG462 in advanced solid tumours, run by Servier Bio-Innovation LLC, active and no longer recruiting.

## Summary

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP is a phase 1/2 interventional study registered as NCT06188702 by Servier Bio-Innovation LLC, with 60 participants enrolled, started 2024-04-29 and due to reach its primary completion in 2027-05-01. Interventions recorded: S095035 and TNG462.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06188702
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP
- Sponsor: Servier Bio-Innovation LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06188702: https://clinicaltrials.gov/study/NCT06188702

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [TNG462](https://onco.cc/drugs/tng462/)
- companies: [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06188702.json